Cancel
Known information
- Holds a MD and PhD from Harbin Medical University and Peking Union Medical College
- Completed postdoctoral training at the Dana-Farber Cancer Institute – Harvard University
- Previously spearheaded oncology biomarker strategies and drug & diagnostics co-development at Genentech
- Identified p110beta as a novel drug target for PTEN-deficient tumors
- Previously held various senior research positions at Novartis Institutes for BioMedical Research
- Awarded the P.A.R.T. Investigatorship Award from the Dana-Farber Cancer Institute
About Predicine
Predicine is a biotech company specializing in genomic profiling tests and algorithms for cancer diagnostics and monitoring, utilizing a liquid biopsy platform and operating CLIA-certified laboratories in the US and China.
Report inaccurate information
